Poor Adherence to Secondary Prophylaxis is Associated with More Severe Rheumatic Valve in Pediatric Patients: A Cross-Sectional Study

Taufiq Ridlo Makhmud 1*, Mohammad Saiful Rohman 1,2, Renny Suwarniati 3, Djanggan Sargowo 2, Faris Wahyu Nugroho 1, Annisa Hasanah 3, Bambang Kusbandono 3, Citra Tarannita 3, Ratih Kusumawardani 3, Sasmojo Widito 2, Heny Martini 2

1 Brawijaya Cardiovascular Research Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.
2 Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.
3 Department of Pediatric, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.

Background: Rheumatic heart disease (RHD) contributed to a large number of proportion among cardiovascular problems in developing county, especially Indonesia. Secondary prophylaxis method using intramuscular injection of Benzathin Penicillin-G (BPG) has been known as the most effective strategy in the prevention of RHD. However, whether this prevention method also resulting in prevention of disease severity in Indonesian patients remained to be examined.

Objectives: This study aimed to assess the difference of rheumatic valve severity in Indonesian pediatric patients between adequate and poor adherence to secondary prophylaxis by using intramuscular BPG injection.

Methods: This cross-sectional study was conducted at Pediatric Cardiology Department of Saiful Anwar General Hospital from November 2018 to June 2019. Patients with documented history of RHD were included. Frequency of intramuscular BPG injection during the last one year was recorded. Adherence was measured using the proportion of days covered (PDC) and adequate adherence was defined as PDC ≥0.90. The severity of RHD was assessed based on the severity of the mitral and / or aortic valve using echocardiography. Bivariate analysis and multivariate logistic regression analysis was used to identify characteristics associated with rheumatic valve severity.

Results: A significant difference of rheumatic mitral and/or aortic valve severity was observed between adequate adherence compared to poor adherence group (p = 0.016). Rheumatic mitral and/or aortic valve were found to be more severe in patients who has one or more episode of ARF recurrence (p = 0.003). Multivariate logistic regression analysis demonstrated that adherence to secondary prophylaxis within the last 1 year has the strongest influence on the severity of rheumatic mitral and/or aortic valve (p = 0.049; OR 7.20).

Conclusion: The adherence to secondary prophylaxis has the strongest related the rheumatic valve severity compared to other factors.

Keywords: Rheumatic heart disease; Secondary prophylaxis; Adherence; Echocardiograph

1. Introduction

Rheumatic heart disease (RHD) is one of the most leading cause of morbidity and mortality of cardiovascular disease in the world. RHD occurs as a complication of acute rheumatic fever (ARF), 35% of patients diagnosed with ARF developed RHD after 1 year and the rate increased to 51% after 10 years. The incidence of ARF in children aged 5-14 years ranges from 300,000-350,000 per year. Therefore, the the risk of RHD raised when the incidence of ARF also high in the population.

Secondary prophylaxis using intramuscular BPG injection has been known as an effective treatment to prevent recurrence of ARF and to prevent the development of RHD for more than six decades. There are still limited references and studies in RHD patients receiving secondary prophylaxis therapy. It remains unclear whether secondary
prophylaxis adherence using intramuscular BPG injection would contribute to significant difference of outcome especially in terms of rheumatic valve severity in Indonesia.

2. Methods

This was an observational analytic study with cross-sectional echocardiographic as end point. Data was also obtained from outpatient medical record at Pediatric Cardiology Clinic. History taking regarding the compliance to BPG injection recorded via phone or direct interview.

The severity of valve abnormalities was assessed using echocardiography. Echocardiography was performed by cardiology residents under supervision of pediatric cardiologist who were experienced in RHD cases. We evaluated valve severity based on quantitative and semi-quantitative methods according to the recommendations of the European Association of Echocardiography for the assessment of valvular regurgitation (2010) and European Association of Echocardiography / American Society of Echocardiography assessment of valve stenosis (2009). We divided the valve severity of RHD into 3 groups i.e mild, moderate, and severe. This classification was made based on rheumatic mitral and/or aortic valve severity according to the Australian Guideline for Prevention, Diagnosis and Management of Acute Rheumatic Fever and Rheumatic Heart Disease (2012).

Adherence was measured using the proportion of days covered (PDC) by intramuscular BPG injection. Adequate adherence was defined as PDC ≥0.90. We divided into 2 groups which were adequate adherence and poor adherence groups, based on the adherence to secondary prophylaxis. Every day of delays from scheduled injection could illustrate the risk of ARF recurrence and the risk of elaborating rheumatic heart valve abnormalities.

The study protocols were conducted in accordance with the Declaration of Helsinki and were approved by the Institutional Review Board, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia. The aims, risks, and benefits of the study were explained to each participant, and they were asked to sign an informed consent form prior to enrollment. Participants were also informed that they could quit at any time during the interview session. Participations in this study were voluntary and no incentive was given.

3. Results

3.1. Patients selection

During November 2018 to June 2019, there were 47 out of 69 pediatric patients diagnosed with RHD who met the inclusion and exclusion study criteria. Twenty-two patients were excluded due to incomplete data, the use of oral secondary prophylaxis, or showing no mitral or aortic valve abnormalities during echocardiography. Other exclusion criteria were congenital heart disease, infective endocarditis, history of valve surgery, and hemodynamic changes due to volume depletion or overload.

3.2. Baseline characteristics

There was no predominance in sex proportion between samples (51.1% male vs. 48.9% female). The mean age of samples was 11.74 years in mild RHD group, 12.43 years in moderate RHD group and 12.5 years in severe RHD group. The first detection of RHD was diagnosed within approximately 9 years old among all groups. The mild RHD group was shown the highest mean body weight (approximately 36 kgs). The nutritional status of patients was mostly normal (55.3%), while the remaining sample were underweight (27.7%) and overweight (17%). Patients who received ACE inhibitors were 25.5% of total sample. The duration of secondary prophylaxis treatment ranged from 12 months to 90 months (mean 33 months) in all RHD groups. There was a total 21.3% of ARF recurrence, and the highest Wilkins score were found in severe RHD group, only 2.1% of sample suffered from severe remodeling according to wilkins score category, as shown in table 1.

| Patient characteristic          | Total (n=47) |
|--------------------------------|-------------|
| Sex                            |             |
| Man                            | 24 (51,1%)  |
| Woman                          | 23 (48,9%)  |
| Age (years) (mean ± sd)         |             |
| Mild RHD                        | 11,74 ± 3,44|
| Moderate RHD                    | 12,43 ± 2,10|
| Severe RHD                      | 12,50 ± 1,72|
| Age at RHD diagnostic (years) (mean ± sd) |         |
| Mild RHD                        | 9,04 ± 3,80 |
| Moderate RHD                    | 9,71 ± 2,19 |
| Severe RHD                      | 9,40 ± 2,46 |
| Weight (mean ± sd)              |             |
| Mild RHD                        | 36,17 ± 11,75|
| Moderate RHD                    | 33,38 ± 17,94|
| Severe RHD                      | 32,70 ± 7,60|
| Treatment duration (mean ± sd)  |             |
| Mild RHD                        | 33,56 ± 19,56|
| Moderate RHD                    | 33,21 ± 16,28|
| Severe RHD                      | 34,90 ± 21,75|

3.3. Main findings

Patients with adequate adherence to secondary prophylaxis in the last 1-year were found to experience mild RHD (66.7%), compared to patients with poor adherence who found to be moderate (45%) and severe RHD (30%). There is a significant difference between adequate compared to poor adherence group in terms of rheumatic valve severity (p = 0.016), see table 2.

Bivariate analysis showed that valve severity was statistically different when ARF re-occurred and the Wilkins score was higher (p = 0.003; p = 0.000, respectively), see table 3. No significant in valve severity in term of age, sex, nutritional status or treatment duration.

Multivariate analysis between adherence to secondary prophylaxis, total ARF recurrence, and Wilkins scores showed that the adherence to secondary prophylaxis variable has the strongest related to the severity of RHD (p = 0.049; OR 7.20) compared to others as shown in table 4.
### Table 2. The effect of adding G. mangostana L. extract on lipid and glycemic profiles after 90 days of treatment

| Adherence          | RHD severity | Total | P value |
|--------------------|--------------|-------|---------|
|                    | Mild         | Moderate | Severe |       |
| Good Adherence     | 18 (66.7%)   | 5 (18.5%) | 4 (14.8%) | 27 (100%) | 0.016* |
| Poor Adherence     | 5 (25%)      | 9 (45%)  | 6 (30%)  | 20 (100%)   |

### Table 3. Bivariate Analysis

| Adherence          | RHD severity | Total | P value |
|--------------------|--------------|-------|---------|
|                    | Mild         | Moderate | Severe |       |
| Sex                |              |         |         |       |
| Woman              | 11 (45.8%)   | 6 (25%)  | 7 (29.2%) | 24 (100%) | 0.336 |
| Man                | 12 (52.2%)   | 8 (34.8%) | 3 (13%)  | 23 (100%)   |
| ARF recurrence in 1 year |          |         |         |       |
| Never              | 22 (51.2%)   | 12 (27.9%) | 9 (20.9%) | 43 (100%) | 0.419 |
| 1x                 | 1 (25%)      | 2 (50%)  | 1 (25%)  | 4 (100%)    |
| Total ARF recurrence |            |         |         |       |
| Never              | 22 (59.5%)   | 10 (27%)  | 5 (13.5%) | 37 (100%) | 0.003** |
| 1x                 | 1 (10%)      | 4 (30%)  | 5 (50%)  | 10 (100%)   |
| Nutritional status |              |         |         |       |
| Underweight        | 3 (23.1%)    | 7 (53.8%) | 3 (23.1%) | 13 (100%) | 0.176 |
| Normal             | 15 (57.7%)   | 4 (15.4%) | 7 (26.9%) | 26 (100%)   |
| Overweight         | 5 (62.5%)    | 3 (37.5%) | 0 (0%)   | 8 (100%)    |
| Wilkins score      | 0 ± 0        | 1.07 ± 1.21 | 3.1 ± 1.20 | 0.000** |
| Wilkins score categorical |       |          |         |       |
| Mild Remodeling    | 23 (50%)     | 14 (30.4%) | 9 (19.6%) | 46 (100%) | 0.157 |
| Severe Remodeling  | 0 (0%)       | 0 (0%)   | 1 (100%) | 1 (100%)    |
| Ace Inhibitor      |              |         |         |       |
| No                 | 20 (57.1%)   | 8 (22.9%) | 7 (20%)  | 35 (100%) | 0.121 |
| Yes                | 3 (25%)      | 6 (50%)  | 3 (25%)  | 12 (100%)   |
| Treatment duration | 33.56±19.5   | 33.21±16.2 | 34.90±21.7 | 0.985 |
| Age                | 9.04 ± 3.80  | 9.71 ± 2.19 | 9.40 ± 2.46 | 0.818 |

### Table 4. Logistic Regression

Variables in the equation

|          | B     | S.E. | Wald | df  | Sig. | Exp(B) | 95% C.I for EXP(B) |
|----------|-------|------|------|-----|------|--------|--------------------|
|          |       |      |      |     |      |        | Lower          | Upper          |
| Step 1c  |       |      |      |     |      |        |                 |                |
| Adherence90(1) | 1.910 | 1.067 | 3.202 | 1  | .074 | 6.750 | .834           | 54.663         |
| TotalRecurrence(1) | .288  | 1.607 | .032 | 1  | .858 | 1.333 | .057           | 31.121         |
| WilkinScore | 19.840 | 4006.255 | .000 | 1  | .996 | 413289521.710 | .000          |
| Constant  | -.2.197 | .745  | 8.690 | 1  | .003 | .111  |                |                |
| Step 2c  |       |      |      |     |      |        |                 |                |
| Adherence90(1) | 1.974 | 1.003 | 3.875 | 1  | .049 | 7.200 | 1.009          | 51.392         |
| WilkinScore | 19.961 | .000  | 1.996 | 466789367.757 | .000 |        |                |                |
| Constant  | -.2.197 | .745  | 8.690 | 1  | .003 | .111  |                |                |

Note: a. Variable(s) entered on step 1: Adherence 90, Total ARF recurrence, Wilkins Score.
4. Discussion

4.1. Adherence to Secondary Prophylaxis and the Severity of RHD

Twenty-seven patients (57.4%) demonstrated adequate adherence to secondary prophylaxis treatment (PDC ≥0.90), whilst 20 patients (42.6%) showed poor adherence (PDC rate was <0.90). Rates of secondary prophylactic treatment adherence varied greatly in various studies, previous study using a cut-off point of ≥0.90 in Brazil showed a total adequate adherence in 71.9% of patients.13 Gasse et al. obtained a total adequate adherence in 54% patients by using cut-off of adherence ≥0.80.12 However, Culliford-Semmens et al. reported adequate adherence of 68.4% patients in New Zealand using the same cut-off.2 Rahmawaty et al. has suggested a total adequate adherence in 58.7% patients, but the cut-off rate used did not clearly state.14 According to previous data it was suggested that our result was concurrence to other. We did not explore further related factors affecting poor compliance in this study.

In contrast to several previous studies which showed a significant difference in valve severity by using an adherence cut-off ≥0.80, this study provides higher adherence (≥0.90) in order to achieve more significant value between mild, moderate, and severe RHD. Based on our data that used a 0.90 adherence cut-off point, the result showed that patients with adequate adherence to secondary prophylactic treatment in the last 1-year experienced milder RHD (66.7%), while patients with poor adherence had more moderate RHD (45%) and even more severe RHD (30%). Further study is warranted to explore the need of higher cut off adherence in Indonesian children correlate to genetic susceptibility or high prevalence in crowded population with poor individual hygiene or other factors.

The Bivariate analysis using chi-square test demonstrated a significant relationship between the level of adherence to secondary prophylaxis with the severity of RHD valve abnormalities (p = 0.016). This result emphasized the need to increase adherence to secondary prophylaxis for RHD patients in Indonesia to prevent more severe valve disease. Concurrence to our study, Stewart et al. have mentioned a trend towards higher adherence was seen among children, more frequent clinic attendees, and patients with less severe disease. No trend was seen between adherence rates in men and women.15 Remond et al. also suggested the importance of register / recall systems, dedicated health teams for delivery of secondary antibiotic prophylaxis, education about ARF and RHD, linkages with the community, and strong staff–patient relationships to improve compliance.14 Rheumatic fever registries have gained considerable popularity as a means of improving treatment adherence. The World Health Organization has promoted the use of ARF registers in developing countries to attempt to coordinate patient management and improve adherence to secondary prophylaxis.15,16

This study result was consistent with many studies which stated that routine secondary prophylaxis followed by adherence to treatment is closely related to the low degree of valve severity. Sanjay et al. in India mentioned that 33% of children with ARF and carditis have shown resolution of heart murmur after 5 years of BPG secondary prophylaxis.17 Arooa-Carr et al. also mentioned that the administration of secondary prophylaxis could reduce the severity of RHD and was associated with regression of heart valve abnormalities in about 50-70% of patients with adequate adherence for a decade.18 There were similarities between our study and other previous studies that poor adherence to secondary prophylaxis was associated with more severe valve abnormalities. Unfortunately, because our study only evaluated echocardiography once in a row, it was unable to assess regression or progression of valve abnormalities.

4.2. ARF Recurrence and RHD Severity

Bivariate analysis between the ARF recurrence in the last 1-year (without secondary prophylaxis) and the severity of RHD showed no significant relationship (p = 0.419). However, further bivariate analysis between the total ARF recurrence (after the administration of secondary prophylaxis treatment) and the severity of RHD found a significant relationship (p = 0.003). This can be explained by a very low recurrence rate of ARF in the last 1-year which only found in 4 patients (8.5%) before the treatment of secondary prophylaxis. However, after the administration of secondary prophylaxis, the total ARF recurrence rate was found in 10 patients (21.3%). Although not a big count, but it was statistically significant after using Fisher exact test, suggesting that this phenomenon was caused by a small size of sample. Further bigger sample might confirm the correlation between recurrence of RF with RHD valve severity.

4.3. Wilkins score and RHD severity

Bivariate analysis between the Wilkins scores and the severity of RHD demonstrated a significant relationship (p = 0.000). The Wilkins score was calculated numerically based on the total score of four parameters (leaflet mobility, valvular thickening, leaflet calcification, and subvalvular thickening).13 Further analysis was attempted using the categorical Wilkins score, which divided into two category: a Wilkins score of ≥5 (severe remodeling / inflammation) and a Wilkins score <5 (minor remodeling / inflammation).14 There was no significant relationship (p = 0.157) between this categorical Wilkins score and the RHD severity. This was due to the number of patients in the severe remodelling / inflammation group is only 1 patient, thus it is difficult to be statistically proven.

Aloui et al. reported that the severity of valve thickening and calcification assessed by echocardiography using the Wilkins score were associated with high levels of Matrix metalloproteinase-3 (MMP-3). High levels of MMP-3, which is a marker of remodeling, are also positively correlated with the severity of the inflammatory process.15 With a fairly high number of mitral valve abnormalities, there should be a significant relationship between Wilkins score and rheumatic valve severity. This was evident in the Wilkins bivariate test using numerical Wilkins score on the severity of RHD. The non significant relationship in Wilkins bivariate testing using categorical 2 groups was due to the low number of patients classified as severe remodeling / inflammation. This was not surprising because the subject of this study was taken from all pediatric thus the process of chronic inflammation and remodeling of the heart valves has not been seen as clear and severe as in adult RHD patients.

There were high number of patients with mitral valve regurgitation in our study, those involving only the mitral valve (70.2%) and those that coincided with the aortic valve (27.7%). Previous study by Mehta et al. (2013) found that mitral valve regurgitation abnormalities were the most common valve abnormalities (48.7%) in RHD.12 Carapetis et al. also mentioned that valve thickening, thickening of the chorda tendinea, and tethering in one or both valves could occur, even in mild valve abnormalities. The mechanism most often was caused by mitral regurgitation in RHD cases.9

The multivariate logistic regression analysis between the adherence to secondary prophylaxis, total ARF recurrence, and Wilkins scores demonstrated that adherence to secondary prophylaxis variable has the strongest relation to the severity of RHD (p = 0.049); OR 7.20. The magnitude of OR obtained is 7.20 which means that the likelihood of patients experiencing a degree of worsened RHD is 7.2 times higher in poor adherent compared to those adequate adherent patients.
5. Conclusion

Our study revealed that poor adherence to secondary prophylaxis is significantly associated with more severe rheumatic valve severity in pediatric patients. In addition, higher Wilkins score and higher rate of total ARF recurrence were significantly associated with rheumatic valve severity. The adherence to secondary prophylaxis has the strongest relation to the rheumatic valve severity compared to other factors. Therefore, higher level of adherence is required to prevent and reduce rheumatic mitral and/or aortic valve severity in pediatric patients in Indonesia.

6. Declarations

6.1. Ethics Approval and Consent to participate
This study was approved by local Institutional Review Board, and all participants have provided written informed consent prior to involve in the study.

6.2. Consent for publication
Not applicable.

6.3. Availability of data and materials
Data used in our study were presented in the main text.

6.4. Competing interests
Not applicable.

6.5. Funding source
Not applicable.

6.6. Authors contributions
Idea/concept: TRM. Design: TRM. Control/ supervision: MSR, DS, RS, SW, HM. Data collection/ processing: TRM, FWN, AH, BK, CT, RK. Extraction/Analysis/interpretation: TRM, MSR, DS, RS, SW, HM. Literature review: TRM, FWN, AH, BK, CT, RK, MSR, DS, RS, SW, HM. Writing the article: TRM. Critical review: MSR, DS, RS, SW, HM. All authors have critically reviewed and approved the final draft and are responsible for the content and similarity index of the manuscript.

6.7. Acknowledgements
We thank to Brawijaya Cardiovascular Research Center.

References

1. Marijon E, Mirabel M, Celemajer DS, et al. Rheumatic Heart Disease. Lancet. 2012; 379: 953–64.

2. Siregar AA. Demam rematik dan penyakit jantung rematik, permasalahan Indonesia. Inauguration Speech of Professor Position at the Faculty of Medicine, University of North Sumatra, Indonesia. 12th April 2008.

3. Burke RJ, and Chang C. Diagnostic Criteria of Acute Rheumatic Fever. Autoimmunity Reviews. 2014; 13: 503–507.

4. Lawrence JG, Carapetis JR, Griffiths K, et al. Acute rheumatic fever and rheumatic heart disease: incidence and progression in the Northern Territory of Australia, 1997 to 2010. Circulation. 2013; 128: 492–501.

5. Culliford-Semmens N, Tilton E, Webb R, et al. Adequate Adherence to Benzathine Penicillin Secondary Prophylaxis Following the Diagnosis of Rheumatic Heart Disease by Echocardiographic Screening. NZMJ. 2017; 130: 50–57.

6. Haran S, Crane N, Kazi S, et al. Effect of Secondary Penicillin Prophylaxis on Valvular Changes in Patients With Rheumatic Heart Disease in Far North Queensland. Aust. J. Rural Health. 2018; 26: 119–125.

7. Lancellotti P, Mouna L, Pierard LA, et al. European Association of Echocardiography Recommendations for Assessment of Valve Regurgitation. European Journal of Echocardiography. 2010. 11: 307–332.

8. Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic Assessment of Valve Stenosis: EAE/ASE Recommendations for Clinical Practice. Journal of the American Society of Echocardiography. 2009; 2(1): 1-16.

9. Carapetis J, Brown A, Maguire G, et al. The Australian Guideline for Prevention, Diagnosis and Management of Acute Rheumatic Fever and Rheumatic Heart Disease, 2nd edition.

10. Camara EJN, dos Santos JM, Silva LSA, et al. Rheumatic Fever Recurrence: Risk Factors and Clinical Characteristics. Clinical Trials and Regulatory Science in Cardiology. 2016; 19: 5–8.

11. Kementrian Kesehatan RI. 2011. Buku Saku mengenai Keputusan Menteri Kesehatan Republik Indonesia Nomer 1995/Menk/es/SK/XII/2010 tentang Standar Antropometri Penilaian Status Gizi Anak.

12. Gasse B, Baroux N, Rouchon B, et al. Determinants Of Poor Adherence To Secondary Antibiotic Prophylaxis For Rheumatic Fever Recurrence On Lifou, New Caledonia: A Retrospective Cohort Study. BMC Public Health. 2013; 13:131.

13. Rahmawaty NK, Iskandar B, Albar H, et al. Faktor Risiko Serangan Berulang Demam Rematik/Penyakit Jantung Rematik. Sari Pediatri. 14(3): 179-84.

14. Rémond MGW, Coyle ME, Mills JE, et al. Approaches to Improving Adherence to Secondary Prophylaxis for Rheumatic Fever and Rheumatic Heart Disease. Cardiology in Review. 2016; 24: 94–98.

15. Stewart T, McDonald R, Currie B. Acute rheumatic fever: Adherence to secondary prophylaxis and follow up of Indigenous patients in the Katherine region of the Northern Territory. Aust. J. Rural Health. 2007; 13: 234–240.

16. WHO program for the prevention of rheumatic fever / rheumatic heart disease in 16 developing countries: report from phase 1 (1986–90). Bulletin of the World Health Organ 1992; 70: 213–218.

17. Saxena A, Mehta A, Ramakrishnan S. Adherence to Benzathine Penicillin in Children With Rheumatic Fever/ Rheumatic Heart Disease: Results from an Indian Pediatric RHD Registry. JACC. 65 (1986–90). Bulletin of the World Health Organ 1992; 70: 213–218.

18. Atatooa-Carr P, Lennon D, Wilson N. Rheumatic Fever Diagnosis, Management, and Secondary Prevention: A New Zealand Guide- line. NZMJ. 2008; 121: 59–69.

19. Soliman OII, Anwar AM, Metawei .K, et al. New Scores for the Assessment of Mitral Stenosis Using Real-Time Three-Dimensional Echocardiography. Curr Cardiovasc Imaging Rep. 2011; 4: 370-377.

20. Aloui S, Wiem Zidi W, Ouali S, et al. Association Of Matrix Metalloproteinase-3 and Endogenous Inhibitors With Inflammatory Markers In Mitral Valve Disease And Calcification. Molecular Biology Reports. 2018; 45: 2135–2143.

21. Mehta A, Saxena S, Juneja R, et al. Characteristics and Outcomes of Indian Children Enrolled in a Rheumatic Heart Disease Registry. International Journal of Cardiology. 2016; 222: 1136–1140.
22. Remenyi B, Wilson N, Stirling J, et al. World Heart Federation Criteria for Echocardiographic Diagnosis of Rheumatic Heart Disease, an Evidence-Based. Nat. Rev. Cardiol. 2012; 9: 297–309.